Global PCSK9 Inhibitors Market Status and Outlook 2018-2025

August 2018 | 155 pages | ID: GD18C783DB4EN
99Strategy

Abstracts

REPORT SNAPSHOT

Key Content of Chapters (Including and can be customized, report is a semifinished version, and it takes 48-72 hours to upgrade)

Part 1:
Terminology Definition, Industry Chain,Industry Dynamics & Regulations and Global Market Overview
Part 2:
Upstream (Raw Materials/Components) & Manufacturing (Procurement Methods & Channels and Cost) , Major Regional Production Overview and Trade Flow
Part 3:
Product Segment Overview and Market Status
Part 4:
Application/End-User Segment Overview and Market Status
Part 5:
Region Segment Overview and Market Status
Part 6:
Product & Application Segment Production & Demand by Region
Part 7:
Market Forecast by Product, Application & Region
Part 8:
Company information, Products & Services and Business Operation (Sales, Cost, Margin etc.)
Part 9:
Market Competition and Environment for New Entrants
Part 10:
Conclusion

Market Segment as follows:

Key Companies

• Amgen
• Eli Lilly
• Sanofi
• Pfizer
• Novartis
• Roche
• Merck
• Alnylam
• AstraZeneca
• Affiris
• BMS
• Ionis Pharmaceuticals
• Cyon Therapeutics
• Daiichi Sankyo

Market by Type

• Epatha Evolocumab
• Praluent Alirocumab
• Bococizumab
• Others

Market by Application

• Clinical Application
• Drug Development
• Others

Contents

PART 1 INDUSTRY OVERVIEW (200 USD)

1.1 PCSK9 Inhibitors Industry
  1.1.1 Market Development
  1.1.2 Terminology Definition in the Report
    1.1.2.1 Production
    1.1.2.2 Demand
    1.1.2.3 Sales Revenue
    1.1.2.4 Ex-factory Price & Sales Price
    1.1.2.5 Cost
    1.1.2.6 Gross Margin
1.2 Products & Services Scope
1.3 Industry Chain
1.4 Industry Dynamics & Regulations
1.5 Global Market Overview

PART 2 UPSTREAM & PRODUCTION (200 USD)

2.1 Raw Materials / Components
2.2 Procurement Methods & Channels
2.3 Cost Structure & Manufacturing
2.4 Industry Capacity
2.5 Production Distribution by Geography
  2.5.1 Production in Major Regions / Countries
  2.5.2 Trade Flow Overview

PART 3 PRODUCT SEGMENT (400 USD)

3.1 Introduction by Type
  3.1.1 Epatha Evolocumab
  3.1.2 Praluent Alirocumab
  3.1.3 Bococizumab
  3.1.4 Others
3.2 Market Status

PART 4 APPLICATION / END-USER SEGMENT (400 USD)

4.1 Introduction by Application
  4.1.1 Clinical Application
  4.1.2 Drug Development
  4.1.3 Others
4.2 Market Status

PART 5 REGIONAL MARKET (600 USD)

5.1 Market Overview
5.2 by Region
  5.2.1 North America
    5.2.1.1 United States Market Size and Growth (2015-2018E)
    5.2.1.2 Canada Market Size and Growth (2015-2018E)
    5.2.1.3 Mexico Market Size and Growth (2015-2018E)
  5.2.2 Europe
    5.2.2.1 Germany Market Size and Growth (2015-2018E)
    5.2.2.2 UK Market Size and Growth (2015-2018E)
    5.2.2.3 France Market Size and Growth (2015-2018E)
    5.2.2.4 Italy Market Size and Growth (2015-2018E)
    5.2.2.5 Spain Market Size and Growth (2015-2018E)
    5.2.2.6 Netherlands Market Size and Growth (2015-2018E)
    5.2.2.7 Poland Market Size and Growth (2015-2018E)
    5.2.2.8 Belgium Market Size and Growth (2015-2018E)
    5.2.2.9 Sweden Market Size and Growth (2015-2018E)
    5.2.2.10 Austria Market Size and Growth (2015-2018E)
    5.2.2.11 Denmark Market Size and Growth (2015-2018E)
    5.2.2.12 Switzerland Market Size and Growth (2015-2018E)
    5.2.2.13 Russia Market Size and Growth (2015-2018E)
  5.2.3 Asia-Pacific
    5.2.3.1 China Market Size and Growth (2015-2018E)
    5.2.3.2 India Market Size and Growth (2015-2018E)
    5.2.3.3 Japan Market Size and Growth (2015-2018E)
    5.2.3.4 Korea Market Size and Growth (2015-2018E)
    5.2.3.5 Australia Market Size and Growth (2015-2018E)
    5.2.3.6 Indonesia Market Size and Growth (2015-2018E)
    5.2.3.7 Thailand Market Size and Growth (2015-2018E)
    5.2.3.8 Malaysia Market Size and Growth (2015-2018E)
    5.2.3.9 Singapore Market Size and Growth (2015-2018E)
    5.2.3.10 Philippines Market Size and Growth (2015-2018E)
  5.2.4 South America
    5.2.4.1 Brazil Market Size and Growth (2015-2018E)
    5.2.4.2 Argentina Market Size and Growth (2015-2018E)
    5.2.4.3 Columbia Market Size and Growth (2015-2018E)
    5.2.4.4 Chile Market Size and Growth (2015-2018E)
    5.2.4.5 Peru Market Size and Growth (2015-2018E)
    5.2.4.6 Puerto Rico Market Size and Growth (2015-2018E)
    5.2.4.7 Ecuador Market Size and Growth (2015-2018E)
  5.2.5 Middle East
    5.2.5.1 Saudi Arabia Market Size and Growth (2015-2018E)
    5.2.5.2 Iran Market Size and Growth (2015-2018E)
    5.2.5.3 UAE Market Size and Growth (2015-2018E)
    5.2.5.4 Oman Market Size and Growth (2015-2018E)
    5.2.5.5 Kuwait Market Size and Growth (2015-2018E)
    5.2.5.6 Iraq Market Size and Growth (2015-2018E)
    5.2.5.7 Turkey Market Size and Growth (2015-2018E)
  5.2.6 Africa
    5.2.6.1 South Africa Market Size and Growth (2015-2018E)
    5.2.6.2 Egypt Market Size and Growth (2015-2018E)
    5.2.6.3 Nigeria Market Size and Growth (2015-2018E)
    5.2.6.4 Algeria Market Size and Growth (2015-2018E)
    5.2.6.5 Angola Market Size and Growth (2015-2018E)
    5.2.6.6 Morocco Market Size and Growth (2015-2018E)
    5.2.6.7 Sultan Market Size and Growth (2015-2018E)

PART 6 MARKET SUBDIVISION (800 USD)

6.1 Regional Production
  6.1.1 Production by Type
    6.1.1.1 Epatha Evolocumab Production by Region
    6.1.1.2 Praluent Alirocumab Production by Region
    6.1.1.3 Bococizumab Production by Region
    6.1.1.4 Others Production by Region
  6.1.2 Production by Application
    6.1.2.1 Clinical Application Production by Region
    6.1.2.2 Drug Development Production by Region
    6.1.2.3 Others Production by Region
6.2 Regional Demand
  6.2.1 Demand by Type
    6.2.1.1 Epatha Evolocumab Demand by Region
    6.2.1.2 Praluent Alirocumab Demand by Region
    6.2.1.3 Bococizumab Demand by Region
    6.2.1.4 Others Demand by Region
  6.2.2 Demand by Application
    6.2.2.1 Clinical Application Demand by Region
    6.2.2.2 Drug Development Demand by Region
    6.2.2.3 Others Demand by Region

PART 7 MARKET FORECAST (200 USD)

7.1 Global Forecast
7.2 Forecast by Type
7.3 Forecast by Application
7.4 Forecast by Region

PART 8 KEY COMPANIES LIST (600 USD)

8.1 Amgen
  8.1.2 Company Information
  8.1.2 Products & Services
  8.1.3 Business Operation
8.2 Eli Lilly
  8.2.1 Company Information
  8.2.2 Products & Services
  8.2.3 Business Operation
8.3 Sanofi
  8.3.1 Company Information
  8.3.2 Products & Services
  8.3.3 Business Operation
8.4 Pfizer
  8.4.1 Company Information
  8.4.2 Products & Services
  8.4.3 Business Operation
8.5 Novartis
  8.5.1 Company Information
  8.5.2 Products & Services
  8.5.3 Business Operation
8.6 Roche
  8.6.1 Company Information
  8.6.2 Products & Services
  8.6.3 Business Operation
8.7 Merck
  8.7.1 Company Information
  8.7.2 Products & Services
  8.7.3 Business Operation
8.8 Alnylam
  8.8.1 Company Information
  8.8.2 Products & Services
  8.8.3 Business Operation
8.9 AstraZeneca
  8.9.1 Company Information
  8.9.2 Products & Services
  8.9.3 Business Operation
8.10 Affiris
  8.10.1 Company Information
  8.10.2 Products & Services
  8.10.3 Business Operation
8.11 BMS
8.12 Ionis Pharmaceuticals
8.13 Cyon Therapeutics
8.14 Daiichi Sankyo

PART 9 COMPANY COMPETITION (500 USD)

9.1 Market by Company
9.2 Price & Gross Margin
9.3 Competitive Environment for New Entrants
  9.3.1 Michael Porter's Five Forces Model
  9.3.2 SWOT

PART 10 RESEARCH CONCLUSION (100 USD)

List Of Tables

LIST OF TABLES

Table PCSK9 Inhibitors Industry Dynamics & Regulations List
Table Global PCSK9 Inhibitors Sales Revenue, Cost and Margin, 2015-2018E
Table Global PCSK9 Inhibitors Market Status by Type 2015-2018E, in USD Million
Table Global PCSK9 Inhibitors Market Status by Application 2015-2018E, in USD Million
Table Global PCSK9 Inhibitors Market Status by Application 2015-2018E, in Volume
Table Global PCSK9 Inhibitors Market by Region 2015-2018E, in USD Million
Table Global PCSK9 Inhibitors Market Share by Region in 2018, in USD Million
Table Global PCSK9 Inhibitors Market by Region 2015-2018E, in Volume
Table Global PCSK9 Inhibitors Market Share by Region in 2018, in Volume
Table Epatha Evolocumab Production Value by Region 2015-2018E, in USD Million
Table Epatha Evolocumab Production Volume by Region 2015-2018E, in Volume
Table Praluent Alirocumab Production Value by Region 2015-2018E, in USD Million
Table Praluent Alirocumab Production Volume by Region 2015-2018E, in Volume
Table Bococizumab Production Value by Region 2015-2018E, in USD Million
Table Bococizumab Production Volume by Region 2015-2018E, in Volume
Table Others Production Value by Region 2015-2018E, in USD Million
Table Others Production Volume by Region 2015-2018E, in Volume
Table Clinical Application Production Value by Region 2015-2018E, in USD Million
Table Clinical Application Production Volume by Region 2015-2018E, in Volume
Table Drug Development Production Value by Region 2015-2018E, in USD Million
Table Drug Development Production Volume by Region 2015-2018E, in Volume
Table Others Production Value by Region 2015-2018E, in USD Million
Table Others Production Volume by Region 2015-2018E, in Volume
Table Epatha Evolocumab Market Size by Region 2015-2018E, in USD Million
Table Epatha Evolocumab Market Size by Region 2015-2018E, in Volume
Table Praluent Alirocumab Market Size by Region 2015-2018E, in USD Million
Table Praluent Alirocumab Market Size by Region 2015-2018E, in Volume
Table Bococizumab Market Size by Region 2015-2018E, in USD Million
Table Bococizumab Market Size by Region 2015-2018E, in Volume
Table Others Market Size by Region 2015-2018E, in USD Million
Table Others Market Size by Region 2015-2018E, in Volume
Table Clinical Application Market Size by Region 2015-2018E, in USD Million
Table Clinical Application Market Size by Region 2015-2018E, in Volume
Table Drug Development Market Size by Region 2015-2018E, in USD Million
Table Drug Development Market Size by Region 2015-2018E, in Volume
Table Others Market Size by Region 2015-2018E, in USD Million
Table Others Market Size by Region 2015-2018E, in Volume
Table GlobalPCSK9 Inhibitors Forecast by Type 2019F-2025F, in USD Million
Table PCSK9 Inhibitors Forecast by Type 2019F-2025F, in Volume
Table PCSK9 Inhibitors Market Forecast by Application / End-User 2019F-2025F, in USD Million
Table PCSK9 Inhibitors Market Forecast by Application / End-User 2019F-2025F, in Volume
Table PCSK9 Inhibitors Market Forecast by Region 2019F-2025F, in USD Million
Table PCSK9 Inhibitors Market Forecast by Region 2019F-2025F, in Volume
Table Amgen Information
Table PCSK9 Inhibitors Sales, Cost, Margin of Amgen
Table Eli Lilly Information
Table PCSK9 Inhibitors Sales, Cost, Margin of Eli Lilly
Table Sanofi Information
Table PCSK9 Inhibitors Sales, Cost, Margin of Sanofi
Table Pfizer Information
Table PCSK9 Inhibitors Sales, Cost, Margin of Pfizer
Table Novartis Information
Table PCSK9 Inhibitors Sales, Cost, Margin of Novartis
Table Roche Information
Table PCSK9 Inhibitors Sales, Cost, Margin of Roche
Table Merck Information
Table PCSK9 Inhibitors Sales, Cost, Margin of Merck
Table Alnylam Information
Table PCSK9 Inhibitors Sales, Cost, Margin of Alnylam
Table AstraZeneca Information
Table PCSK9 Inhibitors Sales, Cost, Margin of AstraZeneca
Table Affiris Information
Table PCSK9 Inhibitors Sales, Cost, Margin of Affiris
Table BMS Information
Table PCSK9 Inhibitors Sales, Cost, Margin of BMS
Table Ionis Pharmaceuticals Information
Table PCSK9 Inhibitors Sales, Cost, Margin of Ionis Pharmaceuticals
Table Cyon Therapeutics Information
Table PCSK9 Inhibitors Sales, Cost, Margin of Cyon Therapeutics
Table Daiichi Sankyo Information
Table PCSK9 Inhibitors Sales, Cost, Margin of Daiichi Sankyo
Table Global PCSK9 Inhibitors Sales Revenue by Company 2015-2017, in USD Million
Table Global PCSK9 Inhibitors Sales Volume by Company 2015-2017, in Volume
Table Global PCSK9 Inhibitors Sales Volume by Company in 2018, in Volume

List Of Figures

LIST OF FIGURES

Figure PCSK9 Inhibitors Picture
Figure PCSK9 Inhibitors Industry Chain Diagram
Figure Global PCSK9 Inhibitors Sales Revenue 2015-2018E, in USD Million
Figure Global PCSK9 Inhibitors Sales Volume 2015-2018E, in Volume
Figure Global PCSK9 Inhibitors Market Status by Type 2015-2018E, in Volume
Figure North America PCSK9 Inhibitors Market Size and Growth 2015-2018E, in USD Million
Figure North America PCSK9 Inhibitors Market Size and Growth 2015-2018E, in Volume
Figure Europe PCSK9 Inhibitors Market Size and Growth 2015-2018E, in USD Million
Figure Europe PCSK9 Inhibitors Market Size and Growth 2015-2018E, in Volume
Figure Asia-Pacific PCSK9 Inhibitors Market Size and Growth 2015-2018E, in USD Million
Figure Asia-Pacific PCSK9 Inhibitors Market Size and Growth 2015-2018E, in Volume
Figure South America PCSK9 Inhibitors Market Size and Growth 2015-2018E, in USD Million
Figure South America PCSK9 Inhibitors Market Size and Growth 2015-2018E, in Volume
Figure Middle East PCSK9 Inhibitors Market Size and Growth 2015-2018E, in USD Million
Figure Middle East PCSK9 Inhibitors Market Size and Growth 2015-2018E, in Volume
Figure Africa PCSK9 Inhibitors Market Size and Growth 2015-2018E, in USD Million
Figure Africa PCSK9 Inhibitors Market Size and Growth 2015-2018E, in Volume
Figure Global PCSK9 Inhibitors Sales Revenue Forecast 2019F-2025F, in USD Million
Figure Global PCSK9 Inhibitors Sales Volume Forecast 2019F-2025F, in Volume
Figure Global PCSK9 Inhibitors Sales Price Forecast 2019F-2025F
Figure Global PCSK9 Inhibitors Gross Margin Forecast 2019F-2025F
Figure Global PCSK9 Inhibitors Sales Revenue by Company in 2018, in USD Million
Figure Global PCSK9 Inhibitors Price by Company in 2018
Figure Global PCSK9 Inhibitors Gross Margin by Company in 2018